Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. 1415456-99-3
2. Lderdvmbiygioi-izvmhkdjsa-n
3. At42613
Molecular Weight | 4409 g/mol |
---|---|
Molecular Formula | C194H312N54O59S2 |
XLogP3 | -12.5 |
Hydrogen Bond Donor Count | 60 |
Hydrogen Bond Acceptor Count | 65 |
Rotatable Bond Count | 137 |
Exact Mass | Da |
Monoisotopic Mass | Da |
Topological Polar Surface Area | 1880 |
Heavy Atom Count | 309 |
Formal Charge | 0 |
Complexity | 10800 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 42 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
NDC Package Code : 71052-025
Start Marketing Date : 2024-01-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73212-088
Start Marketing Date : 2024-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
NDC Package Code : 84347-007
Start Marketing Date : 2025-02-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 73212-088
Start Marketing Date : 2024-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71052-025
Start Marketing Date : 2024-01-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 84347-007
Start Marketing Date : 2025-02-17
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and solutions, offering global API and preparation production services. Co-founded by...
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...
About the Company : It is located in Tianhe hi tech park, Binjiang District, Hangzhou. The company's main researchers have more than ten years of experience in peptide product research and development...
Details:
CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Lead Product(s): Cagrilintide,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: CagriSema
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CagriSema Shows Superior Weight Loss in REDEFINE 2 Trial for Obesity & Diabetes
Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
March 10, 2025
Details:
CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Lead Product(s): Cagrilintide,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: CagriSema
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CagriSema Demonstrates Superior Weight Loss in Adults with Obesity in REDEFINE 1 Trial
Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Details:
People treated with CagriSema (semaglutide) achieved a numerically higher body weight reduction of 15.6% compared to a reduction of 5.1% for people treated with semaglutide and 8.1% with cagrilintide alone.
Lead Product(s): Cagrilintide,Semaglutide
Therapeutic Area: Endocrinology Brand Name: CagriSema
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2022
Lead Product(s) : Cagrilintide,Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk Successfully Completes Phase 2 Trial With Cagrisema in People With Type 2 Diabetes
Details : People treated with CagriSema (semaglutide) achieved a numerically higher body weight reduction of 15.6% compared to a reduction of 5.1% for people treated with semaglutide and 8.1% with cagrilintide alone.
Product Name : CagriSema
Product Type : Peptide
Upfront Cash : Inapplicable
August 22, 2022
ABOUT THIS PAGE